
Viatris Announces US Commercial Launch Of RYZUMVl 0.75%
Healthcare company Viatris Inc. (VTRS) announced Monday the U.S. commercial launch of RYZUMVI (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents in the U.S. RYZUMVI is now the only U.S. commercially available FDA-approved eye drop to reverse dilation. Comprehensive dilated eye exams...